Author:
Zhu Xinping,Kudo Masahisa,Huang Xiangjie,Sui Hehuan,Tian Haishan,Croce Carlo M.,Cui Ri
Abstract
Lung cancer is the leading cause of cancer-related deaths worldwide and non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancer cases. Recent advancements in diagnostic tools, surgical treatments, chemotherapies, and molecular targeted therapies that improved the therapeutic efficacy in NSCLC. However, the 5-years relative survival rate of NSCLC is only about 20% due to the inadequate screening methods and late onset of clinical symptoms. Dysregulation of microRNAs (miRNAs) was frequently observed in NSCLC and closely associated with NSCLC development, progression, and metastasis through regulating their target genes. In this review, we provide an updated overview of aberrant miRNA signature in NSCLC, and discuss the possibility of miRNAs becoming a diagnostic and therapeutic tool. We also discuss the possible causes of dysregulated miRNAs in NSCLC.
Subject
Cell Biology,Developmental Biology
Reference123 articles.
1. MicroRNA-196b inhibits cell growth and metastasis of lung cancer cells by targeting runx2;Bai;Cell. Physiol. Biochem.,2017
2. MicroRNAs: genomics, biogenesis, mechanism, and function;Bartel;Cell,2004
3. MicroRNAs: target recognition and regulatory functions;Bartel;Cell,2009
4. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer;Baumgartner;Mol. Cancer,2018
5. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors;Beg;Invest. New Drugs,2017
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献